Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jan 21;22(1):2.
doi: 10.1007/s11908-020-0712-7.

Fluconazole Prophylaxis in Prevention of Symptomatic Candida Vaginitis

Affiliations
Review

Fluconazole Prophylaxis in Prevention of Symptomatic Candida Vaginitis

Kannika Story et al. Curr Infect Dis Rep. .

Abstract

Due to broad spectrum susceptibility of Candida species to fluconazole, its convenience as an oral agent, and predictable patient tolerance and safety, current practice guidelines recommend the use of long-term suppression regimens of fluconazole as prophylaxis for recurrent vulvovaginal candidiasis (RVVC), as well as in abbreviated doses when known trigger factors emerge and inevitable symptomatic episodes are predictable. However, recent concerns of fluconazole-resistant Candida albicans strains may impact fluconazole use, particularly, concerns of overuse. This literature review discusses current recommendations for prophylaxis of vulvovaginal candidiasis with fluconazole.

Keywords: Boric acid; Candida; Candida albicans; Candida krusei; Candida parapsilosis; Fluconazole; Fluconazole prophylaxis; Fluconazole suppression therapy; Fluconazole-resistance; Nystatin; Recurrent vulvovaginal candidiasis; Resistant candida; Resistant vulvovaginal candidiasis; Vaginitis; Vulvovaginal candidiasis; Yeast infection.

Similar articles

See all similar articles

References

    1. Obstet Gynecol. 2012 Dec;120(6):1407-14 - PubMed
    1. CMAJ. 2019 Feb 19;191(7):E179-E187 - PubMed
    1. Am J Obstet Gynecol. 2008 Dec;199(6):613.e1-9 - PubMed
    1. BMC Womens Health. 2018 Jun 15;18(1):94 - PubMed
    1. Mycoses. 2019 Aug;62(8):692-697 - PubMed

LinkOut - more resources

Feedback